Earnings summaries and quarterly performance for ANI PHARMACEUTICALS.
Executive leadership at ANI PHARMACEUTICALS.
Nikhil Lalwani
Detailed
President and Chief Executive Officer
CEO
CG
Chad Gassert
Detailed
Senior Vice President, Corporate Development & Strategy
CM
Christopher Mutz
Detailed
Senior Vice President, Head of Rare Disease
KD
Krista Davis
Detailed
Senior Vice President and Chief Human Resources Officer
MC
Meredith Cook
Detailed
Senior Vice President, General Counsel and Corporate Secretary
MS
Muthusamy Shanmugam
Detailed
Head of Research & Development and Chief Operating Officer of NJ Operations
OG
Ori Gutwerg
Detailed
Senior Vice President, Generics
SC
Stephen Carey
Detailed
Senior Vice President, Finance and Chief Financial Officer
TR
Thomas Rowland
Detailed
Senior Vice President, Head of Established Brands
Board of directors at ANI PHARMACEUTICALS.
Research analysts who have asked questions during ANI PHARMACEUTICALS earnings calls.
David Amsellem
Piper Sandler Companies
6 questions for ANIP
Also covers: ABBV, ALKS, AMGN +27 more
LS
Leszek Sulewski
Truist Securities
5 questions for ANIP
Also covers: AKBA, AMRX, BHC +6 more
Vamil Divan
Guggenheim Securities
5 questions for ANIP
Also covers: ABBV, ABSI, BHVN +7 more
Gary Nachman
Raymond James
4 questions for ANIP
Also covers: ABBV, ACHV, ADMA +9 more
Faisal Khurshid
Leerink Partners
3 questions for ANIP
Also covers: ABCL, ASND, GERN +7 more
GS
Glen Santangelo
Jefferies
3 questions for ANIP
Also covers: ALGN, BHC, CAH +16 more
BF
Brandon Folkes
Rodman & Renshaw
2 questions for ANIP
Also covers: ACHV, AVDL, COLL +12 more
EK
Ekaterina Knyazkova
Cantor Fitzgerald
2 questions for ANIP
Also covers: AMPH, ELAN, PAHC
TS
Thomas Smith
Leerink Partners
2 questions for ANIP
Also covers: ACRS, ARGX, CLDX +8 more
DK
Daniel Krizay
Guggenheim Partners, LLC
1 question for ANIP
Jeevan Larson
Truist Securities
1 question for ANIP
Also covers: COLL
OL
Oren Livnat
H.C. Wainwright
1 question for ANIP
Also covers: AVDL, CARA, COLL +7 more
Recent press releases and 8-K filings for ANIP.
ANI Pharmaceuticals Reports Record 2025 Results and Provides Strong 2026 Guidance
ANIP
Earnings
Guidance Update
New Projects/Investments
- ANI Pharmaceuticals reported record full-year 2025 revenues of $883.4 million, a 44% year-over-year increase, and adjusted non-GAAP EBITDA of $229.8 million, up 47% year-over-year.
- Key product performance in 2025 included Cortrophin Gel revenues of $347.8 million, growing 76% year-over-year, and generics revenues of $384.1 million, up 28% year-over-year.
- The company provided 2026 net revenue guidance of $1.055 billion to $1.115 billion (19%-26% year-over-year growth) and adjusted non-GAAP EBITDA guidance of $275 million to $290 million (20%-26% year-over-year growth).
- Strategic focus for 2026 includes continued transformation into a rare disease company, with Cortrophin Gel net revenue projected at $540 million to $575 million (55%-65% year-over-year growth), supported by the deployment of a 90-person organization dedicated to acute gouty arthritis flares.
4 days ago
ANI Pharmaceuticals Reports Record 2025 Results and Provides Strong 2026 Guidance
ANIP
Earnings
Guidance Update
New Projects/Investments
- ANI Pharmaceuticals reported record full-year 2025 revenues of $883.4 million, a 44% year-over-year increase, and adjusted non-GAAP EBITDA of $229.8 million, up 47%.
- Cortrophin Gel revenues grew 76% year-over-year to $347.8 million in 2025, significantly contributing to the company's transformation into a rare disease focus.
- For 2026, the company reaffirmed guidance expecting net revenue between $1.055 billion and $1.115 billion, representing 19%-26% year-over-year growth, and adjusted non-GAAP EBITDA between $275 million and $290 million, up 20%-26%.
- Rare disease products are projected to account for approximately 60% of total revenues in 2026, with Cortrophin Gel specifically forecasted to grow 55%-65% year-over-year to $540 million-$575 million.
- Strategic initiatives for 2026 include deploying a 90-person organization by mid-year to capture the opportunity for Cortrophin Gel in acute gouty arthritis flares, alongside continued strong performance from the generics business.
4 days ago
ANI Pharmaceuticals Reports Q4 and Full-Year 2025 Earnings, Provides 2026 Guidance
ANIP
Earnings
Guidance Update
Revenue Acceleration/Inflection
- ANI Pharmaceuticals reported record total net revenues of $883.4 million for FY 2025, a 44% year-over-year increase, and $247.1 million for Q4 2025, a 30% year-over-year increase.
- Adjusted Non-GAAP EBITDA for FY 2025 was $229.8 million, up 47% year-over-year, and $65.4 million for Q4 2025, up 31% year-over-year.
- The company provided 2026 financial guidance, projecting total net revenues between $1,055 million and $1,115 million (19-26% YoY growth) and Adjusted Non-GAAP EBITDA between $275 million and $290 million (20-26% YoY growth).
- Cortrophin Gel revenues grew 76% year-over-year to $347.8 million in FY 2025, and the company expects Rare Disease to represent ~60% of total revenues in 2026 as it accelerates its transformation into a leading Rare Disease company.
4 days ago
ANI Pharmaceuticals Reports Record 2025 Results and Provides Strong 2026 Guidance
ANIP
Earnings
Guidance Update
Revenue Acceleration/Inflection
- ANI Pharmaceuticals reported record financial results for full-year 2025, with total revenues of $883.4 million, up 44% year-over-year, and adjusted non-GAAP EBITDA of $229.8 million, up 47% year-over-year.
- This growth was driven by strong performance in Cortrophin Gel, which saw revenues increase 76% to $347.8 million, and the generics business, which grew 28% to $384.1 million in 2025.
- For 2026, the company provided guidance for total net revenue between $1.055 billion and $1.115 billion, representing 19% to 26% year-over-year growth, and adjusted non-GAAP EBITDA between $275 million and $290 million, up 20% to 26% year-over-year.
- Cortrophin Gel net revenue is projected to be $540 million to $575 million in 2026, a 55% to 65% increase, supported by the deployment of a 90-person organization dedicated to acute gouty arthritis flares.
4 days ago
ANI Pharmaceuticals Reports Record Q4 and Full Year 2025 Results, Reaffirms 2026 Guidance
ANIP
Earnings
Guidance Update
Revenue Acceleration/Inflection
- ANI Pharmaceuticals reported record quarterly net revenues of $247.1 million and full year net revenues of $883.4 million for 2025, representing increases of 29.6% and 43.8% year-over-year, respectively.
- The Rare Disease segment was a significant growth driver, with quarterly net revenue of $131.3 million and full year net revenue of $422.6 million, including Cortrophin Gel net revenues of $111.4 million for Q4 2025 and $347.8 million for full year 2025.
- For the fourth quarter of 2025, the company achieved GAAP net income available to common shareholders of $27.5 million ($1.18 diluted GAAP EPS) and adjusted non-GAAP EBITDA of $65.4 million ($2.33 adjusted non-GAAP diluted EPS).
- For the full year 2025, GAAP net income available to common shareholders was $77.2 million ($3.32 diluted GAAP EPS) and adjusted non-GAAP EBITDA was $229.8 million ($7.89 adjusted non-GAAP diluted EPS).
- The company reaffirmed its full year 2026 financial guidance, projecting total net revenue between $1,055 million and $1,115 million and adjusted non-GAAP diluted EPS between $8.83 and $9.34.
4 days ago
ANI Pharmaceuticals Reports Record Q4 and Full Year 2025 Results, Reaffirms 2026 Guidance
ANIP
Earnings
Guidance Update
Revenue Acceleration/Inflection
- ANI Pharmaceuticals reported record quarterly net revenues of $247.1 million, an increase of 29.6% year-over-year, and record full year net revenues of $883.4 million, up 43.8% year-over-year for 2025.
- The Rare Disease segment was a significant growth driver, with quarterly net revenues of $131.3 million (up 50.8%) and full year net revenues of $422.6 million (up 84.1%), largely due to Cortrophin Gel net revenues of $111.4 million for the quarter and $347.8 million for the full year.
- For the fourth quarter of 2025, adjusted non-GAAP EBITDA was $65.4 million and adjusted non-GAAP diluted earnings per share was $2.33. Full year 2025 results included adjusted non-GAAP EBITDA of $229.8 million and adjusted non-GAAP diluted earnings per share of $7.89.
- The company reaffirmed its full year 2026 financial guidance, expecting total net revenue between $1,055 million and $1,115 million, Cortrophin Gel net revenue between $540 million and $575 million, adjusted non-GAAP EBITDA between $275 million and $290 million, and adjusted non-GAAP diluted EPS between $8.83 and $9.34.
4 days ago
ANI Pharmaceuticals Provides 2026 Guidance and Highlights Rare Disease Transformation
ANIP
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- ANI Pharmaceuticals provided 2026 guidance projecting net revenues of $1,055-$1,115 million (24%-28% growth) and adjusted non-GAAP EBITDA of $275-$290 million (24%-27% growth). This follows 2025 net revenues of $854-$873 million and adjusted non-GAAP EBITDA of $221-$228 million, which grew over 39% and 42% respectively.
- The company is accelerating its transformation into a leading rare disease company, with the rare disease business expected to contribute approximately 60% of total revenues in 2026. Purified Cortrophin Gel, the lead asset, is projected to achieve $540-$575 million in net revenues in 2026, representing 55%-65% growth, driven by existing indications and a significant investment in expanding into acute gouty arthritis flares.
- The generics business, which generated strong cash flows and grew in the low 20s in 2025, is anticipated to be largely flattish in 2026 but will continue to support the rare disease expansion through cash generation.
- ANI Pharmaceuticals ended 2025 with approximately $285 million in cash on the balance sheet and less than 1.7 times net leverage, with plans to accrue cash for future rare disease M&A.
Jan 13, 2026, 11:00 PM
ANI Pharmaceuticals Outlines 2026 Growth Strategy and Financial Guidance
ANIP
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- ANI Pharmaceuticals projects 2026 net revenues of $1,055-$1,115 million, representing 24%-28% growth, and adjusted non-GAAP EBITDA of $275-$290 million, a 24%-27% increase.
- The company is accelerating its transformation into a leading rare disease company, with this segment expected to account for approximately 60% of total revenues in 2026. The lead asset, Purified Cortrophin Gel, is projected to grow 55%-65% to $540-$575 million in net revenues.
- A significant investment of $50 million is planned for 2026 to deploy a 90-person organization by mid-year, focused on expanding Purified Cortrophin Gel's reach into acute gouty arthritis flares.
- The generics business, a strong cash flow generator, is anticipated to be "largely flattish" in 2026 compared to 2025 following robust growth in 2025.
- ANI ended 2025 with approximately $285 million in cash and less than 1.7 times net leverage, with capital allocation prioritizing rare disease business expansion through acquisitions of commercial assets.
Jan 13, 2026, 11:00 PM
ANI Pharmaceuticals Provides 2026 Guidance and Strategic Priorities
ANIP
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- ANI Pharmaceuticals projects strong growth for 2026, with net revenue guidance of $1,055-$1,115 million (24%-28% growth) and adjusted non-GAAP EBITDA guidance of $275-$290 million (24%-27% growth). This follows a robust 2025, where net revenues grew by over 39% to $854-$873 million and adjusted non-GAAP EBITDA grew over 42% to $221-$228 million.
- The company is accelerating its transformation into a leading rare disease company, with the segment expected to comprise approximately 60% of total revenues in 2026. Purified Cortrophin Gel, the lead asset, is projected to grow 55%-65% to $540-$575 million in 2026, supported by a new 90-person organization for acute gouty arthritis flares.
- The generics business, a strong cash flow generator, aims for 10-15 new product launches annually, though 2026 generics revenue is expected to be largely flattish compared to 2025 after significant growth.
- ANI ended 2025 with $285 million in cash and less than 1.7 times net leverage, with capital allocation prioritizing expansion of the rare disease business, likely through acquisitions of commercial assets without clinical risk.
Jan 13, 2026, 11:00 PM
ANI Pharmaceuticals Provides Preliminary 2025 Results and 2026 Financial Guidance
ANIP
Guidance Update
Earnings
New Projects/Investments
- ANI Pharmaceuticals announced preliminary unaudited full year 2025 results, with total net revenues expected within or above the guidance range of $854 million to $873 million, and adjusted non-GAAP EBITDA within or above $221 million to $228 million.
- The company provided full year 2026 financial guidance, forecasting total net revenues between $1,055 million and $1,115 million and adjusted non-GAAP EBITDA of $275 million to $290 million.
- The Rare Disease business is a primary growth driver, with Cortrophin Gel net revenues reaching $347.8 million in 2025 (up 76% year-over-year) and expected to be $540 million to $575 million in 2026. This segment is projected to account for approximately 60% of total net revenues in 2026.
- ANI plans to expand its Rare Disease organization by approximately 90 people by mid-2026 to target the opportunity for Cortrophin Gel in acute gouty arthritis flares.
Jan 12, 2026, 9:15 PM
Quarterly earnings call transcripts for ANI PHARMACEUTICALS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more